1. Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
- Author
-
Mohammed Ghiboub, Jan Koster, Peter D. Craggs, Andrew Y. F. Li Yim, Anthony Shillings, Sue Hutchinson, Ryan P. Bingham, Kelly Gatfield, Ishtu L. Hageman, Gang Yao, Heather P. O’Keefe, Aaron Coffin, Amish Patel, Lisa A. Sloan, Darren J. Mitchell, Thomas G. Hayhow, Laurent Lunven, Robert J. Watson, Christopher E. Blunt, Lee A. Harrison, Gordon Bruton, Umesh Kumar, Natalie Hamer, John R. Spaull, Danny A. Zwijnenburg, Olaf Welting, Theodorus B. M. Hakvoort, Anje A. te Velde, Johan van Limbergen, Peter Henneman, Rab K. Prinjha, Menno P. J. de Winther, Nicola R. Harker, David F. Tough, and Wouter J. de Jonge
- Subjects
Macrophage ,Crohn's disease ,SP140 ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background SP140 is a bromodomain-containing protein expressed predominantly in immune cells. Genetic polymorphisms and epigenetic modifications in the SP140 locus have been linked to Crohn’s disease (CD), suggesting a role in inflammation. Results We report the development of the first small molecule SP140 inhibitor (GSK761) and utilize this to elucidate SP140 function in macrophages. We show that SP140 is highly expressed in CD mucosal macrophages and in in vitro-generated inflammatory macrophages. SP140 inhibition through GSK761 reduced monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation, while inducing the generation of CD206+ regulatory macrophages that were shown to associate with a therapeutic response to anti-TNF in CD patients. SP140 preferentially occupies transcriptional start sites in inflammatory macrophages, with enrichment at gene loci encoding pro-inflammatory cytokines/chemokines and inflammatory pathways. GSK761 specifically reduces SP140 chromatin binding and thereby expression of SP140-regulated genes. GSK761 inhibits the expression of cytokines, including TNF, by CD14+ macrophages isolated from CD intestinal mucosa. Conclusions This study identifies SP140 as a druggable epigenetic therapeutic target for CD.
- Published
- 2022
- Full Text
- View/download PDF